Literature DB >> 2278545

A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study.

M B Bracken1, M J Shepard, W F Collins, T R Holford, W Young, D S Baskin, H M Eisenberg, E Flamm, L Leo-Summers, J Maroon.   

Abstract

Studies in animals indicate that methylprednisolone and naloxone are both potentially beneficial in acute spinal-cord injury, but whether any treatment is clinically effective remains uncertain. We evaluated the efficacy and safety of methylprednisolone and naloxone in a multicenter randomized, double-blind, placebo-controlled trial in patients with acute spinal-cord injury, 95 percent of whom were treated within 14 hours of injury. Methylprednisolone was given to 162 patients as a bolus of 30 mg per kilogram of body weight, followed by infusion at 5.4 mg per kilogram per hour for 23 hours. Naloxone was given to 154 patients as a bolus of 5.4 mg per kilogram, followed by infusion at 4.0 mg per kilogram per hour for 23 hours. Placebos were given to 171 patients by bolus and infusion. Motor and sensory functions were assessed by systematic neurological examination on admission and six weeks and six months after injury. After six months the patients who were treated with methylprednisolone within eight hours of their injury had significant improvement as compared with those given placebo in motor function (neurologic change scores of 16.0 and 11.2, respectively; P = 0.03) and sensation to pinprick (change scores of 11.4 and 6.6; P = 0.02) and touch (change scores, 8.9 and 4.3; P = 0.03). Benefit from methylprednisolone was seen in patients whose injuries were initially evaluated as neurologically complete, as well as in those believed to have incomplete lesions. The patients treated with naloxone, or with methylprednisolone more than eight hours after their injury, did not differ in their neurologic outcomes from those given placebo. Mortality and major morbidity were similar in all three groups. We conclude that in patients with acute spinal-cord injury, treatment with methylprednisolone in the dose used in this study improves neurologic recovery when the medication is given in the first eight hours. We also conclude that treatment with naloxone in the dose used in this study does not improve neurologic recovery after acute spinal-cord injury.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2278545     DOI: 10.1056/NEJM199005173222001

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  400 in total

1.  Design of CRASH trial. Evidence shows that quality of trial by Faupel et al is good and therefore should not be excluded.

Authors:  P Alderson
Journal:  BMJ       Date:  1999-10-16

2.  High dose methylprednisolone must be given for 24 or 48 hours after acute spinal cord injury.

Authors:  M B Bracken
Journal:  BMJ       Date:  2001-04-07

Review 3.  Corticosteroids in head injury--the CRASH trial.

Authors:  D Yates; B Farrell; G Teasdale; P Sandercock; I Roberts
Journal:  J Accid Emerg Med       Date:  1999-03

4.  Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review.

Authors:  S Sauerland; M Nagelschmidt; P Mallmann; E A Neugebauer
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

5.  Methylprednisolone for acute spinal cord injury: not a standard of care.

Authors:  Herman Hugenholtz
Journal:  CMAJ       Date:  2003-04-29       Impact factor: 8.262

Review 6.  Biomaterial Approaches to Modulate Reactive Astroglial Response.

Authors:  Jonathan M Zuidema; Ryan J Gilbert; Manoj K Gottipati
Journal:  Cells Tissues Organs       Date:  2018-12-05       Impact factor: 2.481

Review 7.  Transplantation of umbilical cord blood stem cells for treating spinal cord injury.

Authors:  Dong-Hyuk Park; Jeong-Hyun Lee; Cesario V Borlongan; Paul R Sanberg; Yong-Gu Chung; Tai-Hyoung Cho
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

Review 8.  Triage tools for detecting cervical spine injury in pediatric trauma patients.

Authors:  Annelie Slaar; M M Fockens; Junfeng Wang; Mario Maas; David J Wilson; J Carel Goslings; Niels Wl Schep; Rick R van Rijn
Journal:  Cochrane Database Syst Rev       Date:  2017-12-07

Review 9.  Progress of mesenchymal stem cell therapy for neural and retinal diseases.

Authors:  Tsz Kin Ng; Veronica R Fortino; Daniel Pelaez; Herman S Cheung
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

Review 10.  Hypertonic saline: a clinical review.

Authors:  R Tyagi; K Donaldson; C M Loftus; J Jallo
Journal:  Neurosurg Rev       Date:  2007-06-16       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.